Last updated: May 26, 2026
Potassium chloride and sodium chloride are widely sourced, with supply concentrated in a small set of specialty chemical producers and US and global sterile/solid oral and parenteral drug manufacturers. The supplier map breaks into three layers: (1) commodity chemical producers (chlor-alkali brine, salt mining, potassium feedstocks), (2) pharmaceutical-grade API producers (including specialty crystallization and purification), and (3) finished-dose drug product manufacturers that supply hospitals, pharmacies, and distributors in bulk.
What companies supply potassium chloride API and pharmaceutical-grade bulk powder?
Short answer: Supply is dominated by chemical producers with vertically integrated salt and potassium operations, plus pharmaceutical API manufacturers that refine potassium chloride to USP/EP specifications and supply contract manufacturing and labelers.
Key API and bulk producers
Potassium chloride is typically produced from sylvite (KCl) ore and refined through dissolution, crystallization, and drying. Major global suppliers of potassium chloride as a chemical include:
- K+S / KSB (via historical assets and brands)
- ICL Group
- Uralkali
- Sino-Kali (China-based producers; brand names vary by region)
- Compass Minerals (historically active in salts and potassium feedstocks depending on product lines)
Pharmaceutical-grade potassium chloride frequently comes from these chemical supply chains, then is converted into USP-compliant API by refiners/labelers.
How pharmaceutical “API suppliers” differ from chemical suppliers
For procurement, “API suppliers” often mean:
- API manufacturers listing Potassium Chloride as an active ingredient with FDA drug establishment registrations and cGMP systems; and
- contract packaging and labelers that market “USP potassium chloride” as an API-like material for supplements, oral solutions, and injectables.
Because potassium chloride is an established commodity, many finished-dose manufacturers source from multiple upstream API sources to manage availability and price cycles.
What companies supply sodium chloride API and USP-grade salt for pharmaceutical use?
Short answer: Sodium chloride supply is dominated by large-scale salt mining and chlor-alkali ecosystem producers, then converted to pharmaceutical-grade through purification, grain sizing, and controlled impurities.
Key chemical supply sources
Sodium chloride is sourced from:
- Solar evaporation (coastal)
- Brine wells and underground mining
- Salt byproducts from industrial processes, including chlor-alkali operations
Major global producers include:
- INOVYN (Ineos/Salt ecosystems depending on region and corporate structure)
- Escofet / Spanish salt producers (regionally important for Europe)
- SEL (US and Canada salt systems vary by product line)
- Compass Minerals (salt operations in North America)
Pharmaceutical-grade conversion
Pharmaceutical sodium chloride requires tighter specifications for:
- Total impurities (Ca, Mg, SO4, Br, heavy metals)
- Particle size and consistent dissolution
- Sterility assurance where used for parenterals after formulation and filtration
Procurement for injectables typically relies on finished-dose manufacturers and their validated sterile processes rather than direct purchase of chemical-grade salt.
Which firms manufacture finished-dose potassium chloride (tablets, oral solutions, injections)?
Short answer: Finished-dose potassium chloride is produced by large US generic players with sterile and solid-dose capacity, plus specialty sterile and contract manufacturers for injectable products.
Product types and typical supplier segments
- Oral tablets and extended-release: dominated by generic oral-solid manufacturers
- Oral solutions and effervescent formulations: solid-dose and liquid formulators, often through contract manufacturing
- Injectable potassium chloride: usually from sterile manufacturers with aseptic fill-finish
Supplier concentration risk
Potassium chloride injectable supply can tighten during:
- sterile fill-finish capacity constraints
- raw material quality disputes (impurities or lot traceability)
- FDA inspection outcomes or import clearance issues
For business planning, diversify across multiple finished-dose labelers and maintain alternate procurement paths.
Which firms manufacture finished-dose sodium chloride (0.9% saline, sterile solutions)?
Short answer: Sodium chloride 0.9% for injection is produced by a broad base of sterile generic and hospital suppliers, with major contracts managed by large generics and sterile CDMOs.
Why saline procurement behaves differently
- Sodium chloride for injection is formulation-simple but manufacturing-sensitive due to sterility assurance, container closure integrity, and endotoxin control.
- Supply is strongly tied to aseptic processing and fill-finish capacity (vials, bags, and irrigation formats).
- Hospitals often standardize on a small number of GPO-supported SKUs, which can reduce effective competition at the point of care.
What does the supplier landscape look like in the US for potassium chloride and sodium chloride drugs?
Two-track model
- US FDA-regulated finished-dose manufacturing (labeler, NDC holder, sterile manufacturing site)
- Upstream API/chemical supply (often global, with pharmaceutical-grade conversion)
This means a “supplier” procurement strategy should separate:
- NDC drug product source (who makes the finished dosage)
- API/chemical source (where the material is purified and certified)
What is the Orange Book status for potassium chloride and sodium chloride products?
Short answer: Potassium chloride and sodium chloride are generally old, commodity drugs where exclusivity and patent estates vary by formulation and container, but the active ingredient itself often does not carry enforceable primary patents in the way that newer biologics or specialty drugs do.
Practical implication
Patent risk is usually lower for:
- basic immediate-release solid or standard 0.9% saline formulations
Patent risk increases when the product has:
- specific controlled-release technologies,
- particular container and delivery system improvements,
- sterile system innovations, or
- specific method-of-use claims (less common for commodity salts).
How many pharmaceutical suppliers exist for these salts?
Short answer: The number of active suppliers is large for finished-dose salts, but the number of sterile fill-finish capable sites is smaller. For injectables, the constraint is typically manufacturing capacity rather than API scarcity.
Procurement reality
- Oral salts tend to have broader supplier availability.
- Injectable salts tend to show periodic tightening around sterile capacity.
What generic entry risks exist for potassium chloride and sodium chloride?
Short answer: For most conventional solid oral or 0.9% saline products, generic entry risk is driven less by IP and more by:
- cGMP manufacturing verification,
- sterility assurance and validation,
- container closure integrity,
- quality system strength, and
- import and inspection history.
Which distribution channels dominate hospital and retail supply?
- GPO contracts and national wholesalers for hospital saline and electrolyte replacement
- Retail pharmacy channels for oral tablets and solutions
- Institutional pharmacy (IDNs) purchasing through group contracting and bid cycles
In practice, buyer leverage is exercised through:
- contract pricing tied to distribution and GPO formularies,
- dual-source qualification programs,
- and inventory buffers during lead-time disruptions.
How to build a robust supplier map for potassium chloride and sodium chloride procurement
Step 1: Map by dosage form and route
- Oral solid (tablets)
- Oral liquid (solutions)
- Injectable (vials, bags)
- Irrigation and large-volume sterile formats (saline)
Step 2: Map by manufacturing site
- Identify whether each supplier has sterile manufacturing capability for injectables
- Confirm alternate sites and tech transfer readiness
Step 3: Map by quality documentation
- USP compliance certificates (or equivalent)
- CoA traceability and impurity profiles for key ions and metals
- For sterile products: endotoxin, sterility assurance batch release, and sterility test strategy documentation
Step 4: Map by upstream redundancy
- Maintain multiple API/chemical upstream sources for contingency
- Check whether each finished-dose manufacturer qualifies alternate lots and upstream suppliers
Key Takeaways
- Potassium chloride and sodium chloride are commodity salts with broad upstream chemical availability but narrower constraints for sterile injectable capacity.
- Supplier analysis should focus on finished-dose manufacturing sites for injectables and oral-solid manufacturing capacity for tablets and solutions.
- IP risk is usually limited for baseline salt products; quality and manufacturing execution dominate procurement risk.
- For injectable procurement, dual sourcing across labelers and verified sterile fill-finish capabilities is the most effective mitigation against supply volatility.
FAQs
1) Who are the main suppliers of potassium chloride for pharmaceuticals in the US?
Large generic oral-solid and sterile manufacturers supply the US market, sourced from multiple upstream chemical refiners. Finished-dose labelers and NDC holders matter most for procurement.
2) Are potassium chloride injectables more supply-constrained than oral tablets?
Yes. Injectable salts depend on sterile fill-finish capacity and validated sterility assurance, making supply more sensitive to manufacturing constraints than oral tablets.
3) What matters most when sourcing sodium chloride 0.9% for injection?
Sterile manufacturing capability, validated aseptic processing, container-closure integrity, and consistent endotoxin and sterility release performance.
4) What upstream chemical producers supply sodium chloride for pharmaceutical-grade use?
Salt mining and chlor-alkali ecosystem producers supply bulk sodium chloride that is then purified and validated for pharmaceutical use through pharmaceutical-grade conversion steps.
5) Do patents restrict generic availability for potassium chloride or sodium chloride?
For standard formulations, patents are usually not the primary constraint. Quality system capability, cGMP readiness, and sterile/solid-dose manufacturing validation drive most competition.
References
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- US Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- US Food and Drug Administration. NDC Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/ndc-directory
